By Staff Reports
(DGIwire) – Post-traumatic stress disorder (PTSD) can happen to anyone who has experienced a traumatic event, according to the National Center for PTSD, a division of the U.S. Department of Veterans Affairs. The National Center for PTSD also notes that about seven or eight out of every 100 people will have PTSD at some point in their lives, and about eight million adults have PTSD during a given year.
Military service members who have seen combat can easily experience the effects of PTSD. As the National Center for PTSD reports, the number of veterans with PTSD varies by service area:
- Operations Iraqi Freedom (OIF) and Enduring Freedom (OEF): In 2008, the RAND Corporation’s Center for Military Health Policy Research examined the prevalence of PTSD among OIF and OEF service members. Among the 1,938 participants, the prevalence of PTSD at the time of the study was 13.8 percent. About 11-20 percent of these veterans have PTSD in a given year.
- Gulf War (Desert Storm): A study estimating the prevalence of PTSD in a population-based sample of 11,441 Gulf War veterans from 1995 to 1997 determined that 12.1 percent of sample veterans had PTSD at the time and about 12 percent have PTSD in a given year.
- Vietnam War: The National Vietnam Veterans Readjustment Study, conducted between 1986 and 1988, comprised interviews of 3,016 U.S. veterans. It concluded that the estimated lifetime prevalence of PTSD among these veterans was 30.9 percent for men and 26.9 percent for women. Among Vietnam theater veterans, 15.2 percent of males and 8.1 percent of females were currently diagnosed with PTSD at the time the study was conducted.
Though there appears to be a higher prevalence of PTSD in military veterans, researchers are making progress in understanding how PTSD works and what treatments have the potential to be most effective. In fact, there are some recent studies which suggest that specific sleep treatments in the veteran population could lead to significant improvement in sleep and global PTSD symptoms.
“Many people who have experienced military-related PTSD directly, or who have a family member who is affected by it, are aware that disturbed sleep is one of the major symptoms. It is important for these individuals to learn more about ongoing research that focuses on this symptom which may represent a new approach to treat the overall symptoms of PTSD,” says Seth Lederman, MD, the CEO of Tonix Pharmaceuticals, which is developing innovative pharmaceutical products to address public health challenges, with its lead clinical candidate, TNX-102 SL*, focusing on PTSD. Based on the encouraging results in an earlier study with TNX-102 SL in a population with military-related PTSD, the U.S. Food and Drug Administration recently granted Breakthrough Therapy designation to TNX-102 SL for the treatment of PTSD.
Those who were in the military and think they may be affected by PTSD should consider speaking to their doctor about the latest clinical research study involving an investigational new drug as a treatment for PTSD, the HONOR study, a Phase 3 clinical research study sponsored by Tonix Pharmaceuticals. At approximately 35 sites across the U.S., about 550 military PTSD patients will receive either the investigational new drug, TNX-102 SL or placebo sublingual tablets, once-daily at bedtime.
To see if you or someone you know is pre-qualified to participate in this research study, please access the study website for this ongoing research project, TheHonorStudy.com, and learn more about it at https://clinicaltrials.gov/show/NCT03062540. The HONOR study is open to veterans or those currently serving in any branch of the military or as a military contractor.
Currently there are no satisfactory approved drug treatments for military-related PTSD. The investigational new drug used in the HONOR study represents a new approach to treating the condition. While symptoms of PTSD may improve or worsen while taking part in this study, participation will provide information about the study drug, a new approach to treating PTSD, that might benefit others with the condition in the future.
* TNX-102 SL is an investigational new drug and has not been approved for any indication.